NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences. Bank of America Securities 2025 Health Care Conference (Las Vegas, NV)Presenter: Francesca Barone, MD, PhD, Candel’s Chief Scient ...

NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Company’s phase ...

About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. She earned a Bachelo ...

NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN- 2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radioth ...

Core Insights - Candel Therapeutics Inc has presented promising clinical data from a Phase 2a study of its immunotherapy candidate CAN-2409 for advanced non-small cell lung cancer, particularly in patients who have exhausted standard treatment options [1][2] - The study indicates that CAN-2409 may double the expected median overall survival for patients who have failed multiple lines of chemotherapy and immune checkpoint inhibitors [2][6] Patient Population - The study enrolled patients with advanced non-small cell lung cancer, primarily those with stage four metastatic disease and poor prognostic indicators, including low PD-L1 expression and a history of smoking [1][4][5] - 90% of participants had stage four metastatic disease and had previously failed all available treatments, indicating a very poor prognosis [4][5] Clinical Outcomes - The results showed that 37% of patients were still alive two years after treatment with CAN-2409, which is significantly longer than expected for this patient population [3][6] - Some patients have survived beyond three or four years, which is notable given their progressive metastatic lung cancer [3] Treatment Comparison - The standard of care for this patient population is docetaxel chemotherapy, which has a median overall survival of no more than 10.8 months [5] - CAN-2409 has shown potential to extend overall survival significantly beyond this benchmark, providing hope for patients with limited options [6][9] Future Steps - The company plans to conduct a larger, registration-enabling clinical trial to further validate these findings, aligning with key academic experts and the FDA [6][7] - The timeline for this next phase has not yet been announced, but the company is actively engaging with experts to expedite the process [7] Broader Implications - The application of CAN-2409 may extend beyond lung cancer, with indications of similar efficacy in pancreatic cancer, another challenging disease [8] - The treatment is generally well tolerated, with mild flu-like symptoms lasting less than 24 hours, and requires only two administrations to educate the patient's immune system to control the tumor [9]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy regimens, and presented with multiple negative prognostic factors at enrollment (90% of the patients had stage IV disease, most patients had low or undetectable PDL-1 expression, > 90% were current or former smokers, and most patients had failed multiple lines of chemotherapy)mOS of 21.5 months was ...

Core Viewpoint - Candel Therapeutics, Inc. (CADL) has experienced a 21% decline in stock price over the past four weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be exhausting [2][4]. - This pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near its opening price, reflecting buying interest [3][4]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [4]. Fundamental Analysis - Recent upward revisions in earnings estimates for CADL serve as a bullish indicator, correlating strongly with near-term stock price movements [6]. - The consensus EPS estimate for the current year has increased by 3.5% over the last 30 days, indicating analysts' optimism about the company's earnings potential [7]. - CADL holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Candel Therapeutics has entered a strategic commercial partnership with IDEA Pharma to enhance the development and commercialization of its lead asset, CAN-2409, which is focused on cancer treatment [1][3][4] Group 1: Partnership Details - The partnership will provide Candel with strategic commercial input from IDEA throughout the development and commercialization process for CAN-2409 [1][3] - IDEA Pharma will assist in guiding Candel's commercial strategy and support its projects related to CAN-2409, leveraging their expertise in oncology commercialization [3][4] - This collaboration is expected to last through 2026, coinciding with Candel's preparation for a Biologics License Application (BLA) submission for CAN-2409 [4] Group 2: Clinical Data and Product Information - CAN-2409 has shown promising results in a phase 3 clinical trial for localized prostate cancer, demonstrating a 30% reduction in disease recurrence and an 80.4% pathological complete response rate compared to 63.6% in the placebo group [2][9] - The product is an investigational, off-the-shelf, replication-defective adenovirus designed to induce an immune response against tumors by delivering the HSV-tk gene [7][8] - Candel is also evaluating CAN-2409 in non-small cell lung cancer (NSCLC) and has reported significant survival benefits in other cancer types, including pancreatic ductal adenocarcinoma (PDAC) [9][10] Group 3: Company Background - Candel Therapeutics is focused on developing multimodal biological immunotherapies to elicit systemic anti-tumor immune responses [10] - The company has established two clinical-stage platforms based on genetically modified adenovirus and HSV gene constructs, with CAN-2409 being the lead candidate from the adenovirus platform [10] - Candel's other candidate, CAN-3110, is currently in a phase 1b clinical trial for recurrent high-grade glioma, showing promising results in terms of overall survival [10]